In biopharmaceutical development, demonstrating efficacy and toxicity is a major milestone to entering human clinical trials. Most companies lack the internal resources to support all of their nonclinical development needs, relying on outsourcing some or all aspects of their program to nonclinical CROs. Knowing the technical challenges involved in outsourcing your program plays a critical role in bringing your drug to market and can mean the difference between meeting your next milestone on time or experiencing delays.
On June 10, Sinclair's Senior Vice President of Research and Operations, Scott E. Boley, PhD, DABT, will share insight on how to plan for obstacles drug developers will face in outsourcing nonclinical research and how to avoid critical missteps that can affect your program and timeline.
In this webinar you will learn:
- How clearly defined communications and protocols can avoid costly issues
- What to look for when selecting a nonclinical CRO
- How to get the most out of your pre-IND meeting
- What your CRO needs to know about your test article
Register for the webinar